

**Table 3:** Gains in hours per year per patient by using subcutaneous instead of intravenous daratumumab formulation.

	<b>Gain (hours/year/patient)</b>
NDMM ineligible for ASCT: DRd	85.94
NDMM ineligible for ASCT: DVMP	82.36
NDMM eligible for ASCT: DVTd*	60.86
MM from 2nd line: DRd	85.94
MM from 2nd line: DVd	78.78
MM from 3rd line: daratumumab monotherapy	85.94

\*: Includes induction and consolidation only, ASCT: autologous stem cell transplant, SC: subcutaneous, DRd: daratumumab/lenalidomide/dexamethasone, DVd: daratumumab/bortezomib/dexamethasone, DVTd: daratumumab/bortezomib/thalidomide/dexamethasone, MM: multiple myeloma, IV: intravenous, DVMP: daratumumab/bortezomib/melphalan/prednisolone, NDMM: newly diagnosed multiple myeloma